PVLA Palvella Therapeutics Inc.
Price (delayed)
$26.97
Market cap
$297.18M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$7.83
Enterprise value
$213.57M
Highlights
Palvella Therapeutics's equity has surged by 184% YoY
Palvella Therapeutics's quick ratio has soared by 124% YoY and by 46% from the previous quarter
The net income has dropped by 193% year-on-year and by 164% since the previous quarter
The EPS has plunged by 167% from the previous quarter
Key stats
What are the main financial stats of PVLA
Market
Valuations
Earnings
Shares outstanding
11.02M
Market cap
$297.18M
Enterprise value
$213.57M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.57
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$14.1M
Net income
-$17.43M
EBIT
-$13.12M
EBITDA
-$13.12M
Free cash flow
-$10.84M
Per share
Balance sheet
Liquidity
EPS
-$7.83
EPS diluted
-$7.83
Free cash flow per share
-$4.87
Book value per share
$47.42
Revenue per share
$0
TBVPS
$39.64
Total assets
$88.23M
Total liabilities
$25.63M
Debt
$0
Equity
$62.61M
Working capital
$76.2M
Debt to equity
0
Current ratio
7.33
Quick ratio
6.97
Net debt/EBITDA
6.37
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-42.7%
Return on equity
-58.3%
Return on invested capital
N/A
Return on capital employed
-17.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PVLA stock price
How has the Palvella Therapeutics stock price performed over time
Intraday
14.33%
1 week
-3.44%
1 month
39.24%
1 year
N/A
YTD
124.75%
QTD
-3.64%
Financial performance
How have Palvella Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$14.1M
Net income
-$17.43M
Gross margin
N/A
Net margin
N/A
The net income has dropped by 193% year-on-year and by 164% since the previous quarter
The revenue has soared by 100% from the previous quarter
The company's gross profit has surged by 100% QoQ
The operating income has contracted by 19% YoY
Growth
What is Palvella Therapeutics's growth rate over time
Valuation
What is Palvella Therapeutics stock price valuation
P/E
N/A
P/B
0.57
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has plunged by 167% from the previous quarter
Palvella Therapeutics's equity has surged by 184% YoY
PVLA's P/B is 83% below its 5-year quarterly average of 2.9 and 38% below its last 4 quarters average of 0.8
The revenue has soared by 100% from the previous quarter
Efficiency
How efficient is Palvella Therapeutics business performance
Palvella Therapeutics's ROA has plunged by 133% from the previous quarter
PVLA's return on equity has dropped by 110% year-on-year
Dividends
What is PVLA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PVLA.
Financial health
How did Palvella Therapeutics financials performed over time
PVLA's current ratio has soared by 129% year-on-year and by 52% since the previous quarter
Palvella Therapeutics's quick ratio has soared by 124% YoY and by 46% from the previous quarter
The debt is 100% lower than the equity
Palvella Therapeutics's equity has surged by 184% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.